Platelet and Immunity in Transfusion Medicine

Platelets are classically used in the clinic to maintain hemostasis, while recent evidence has shown the important role for platelets in the host inflammatory and immune responses. In fact, platelets in vivo produce different mediators such as cytokines or chemokines, which may be involved in the course of disease treatment, thus platelets transfusion is often an effective therapy in many cases. It is well known that platelets can regulate neu - trophils, lymphocytes and other immune cells behavior in immune response, thus direct-ing these immune cells onto the damaged tissues, organs or infected sites. On the other hand, platelets can induce neutrophil extracellular traps release in response to bacterial or viral infection. All the characterized novel profile of platelet, if not all, at least in some situations, should be take into consideration when platelets have to be transfused into patients.

[1]  Yan Zhou,et al.  Platelet Immunology in China: Research and Clinical Applications. , 2017, Transfusion medicine reviews.

[2]  Z. Wang,et al.  Essential roles for platelets during neutrophil-dependent or lymphocyte-mediated defense against bacterial pathogens , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  Jannetta S. Steyn,et al.  Circular RNA enrichment in platelets is a signature of transcriptome degradation. , 2016, Blood.

[4]  L. Steinmetz,et al.  Inflammation-Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-like Megakaryocyte Progenitors. , 2015, Cell stem cell.

[5]  S. Meuth,et al.  Platelets induce apoptosis via membrane-bound FasL. , 2015, Blood.

[6]  J. Di Cristofaro,et al.  Identification of anti-HPA-1a allo-antibodies using IgG platelet antibody detection and crossmatch system assay with Galileo Echo , 2015, Platelets.

[7]  M. Kuehnert,et al.  Transfusion‐related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012 , 2015, Transfusion.

[8]  Shenmin Zhang,et al.  Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and Thrombosis , 2022 .

[9]  R. Rohilla,et al.  To Evaluate Antimicrobial Properties of Platelet Rich Plasma and Source of Colonization in Pressure Ulcers in Spinal Injury Patients , 2015 .

[10]  Shoudong Wang,et al.  Association between transforming growth factor β1 and atrial fibrillation in essential hypertensive patients , 2015, Clinical and experimental hypertension.

[11]  S. Saidman,et al.  Anti‐HLA alloantibodies in surgical patients refractory to platelet transfusion , 2014, American journal of hematology.

[12]  Meiyun Fang,et al.  The cytokines (IFN-gamma, IL-2, IL-4, IL-10, IL-17) and Treg cytokine (TGF-beta1) levels in adults with immune thrombocytopenia. , 2014, Die Pharmazie.

[13]  M. Marcacci,et al.  Platelet-rich plasma affects bacterial growth in vitro. , 2014, Cytotherapy.

[14]  C. Lass‐Flörl,et al.  Platelet immunology in fungal infections , 2014, Thrombosis and Haemostasis.

[15]  Michael R. Yeaman,et al.  Platelets: at the nexus of antimicrobial defence , 2014, Nature Reviews Microbiology.

[16]  Abdimajid Osman,et al.  Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function , 2014, Platelets.

[17]  P. Baumann,et al.  Platelet mitochondrial membrane depolarization reflects disease severity in patients with sepsis and correlates with clinical outcome , 2014, Critical Care.

[18]  K. Fox,et al.  The Uncoupling of Monocyte–Platelet Interactions from the Induction of Proinflammatory Signaling in Monocytes , 2013, The Journal of Immunology.

[19]  GrasChristiane,et al.  HLA-Universal Platelet Transfusions Prevent Platelet Refractoriness in a Mouse Model , 2013 .

[20]  C. Garlanda,et al.  Platelet-macrophage partnership in innate immunity and inflammation , 2013, Nature Immunology.

[21]  P. Kubes,et al.  Nucleation of platelets with bloodborne pathogens on Kupffer cell precedes other innate immunity and contributes to bacterial clearance , 2013, Nature Immunology.

[22]  J. Münch,et al.  Platelet activation suppresses HIV-1 infection of T cells , 2013, Retrovirology.

[23]  F. Cunningham,et al.  Equine platelets inhibit E. coli growth and can be activated by bacterial lipopolysaccharide and lipoteichoic acid although superoxide anion production does not occur and platelet activation is not associated with enhanced production by neutrophils. , 2013, Veterinary immunology and immunopathology.

[24]  R. Würzner,et al.  Aspergillus fumigatus activates thrombocytes by secretion of soluble compounds. , 2013, The Journal of infectious diseases.

[25]  N. Marwaha,et al.  Treatment With Platelet-Rich Plasma Is More Effective Than Placebo for Knee Osteoarthritis , 2013, The American journal of sports medicine.

[26]  M. Blajchman,et al.  Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future , 2013, Transfusion.

[27]  B. Pozzetto,et al.  Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. , 2012, Clinical immunology.

[28]  R. Kotb,et al.  Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia , 2012, Transfusion.

[29]  B. Coller,et al.  Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. , 2012, Blood.

[30]  Robert A. Campbell,et al.  Novel Anti-bacterial Activities of β-defensin 1 in Human Platelets: Suppression of Pathogen Growth and Signaling of Neutrophil Extracellular Trap Formation , 2011, PLoS pathogens.

[31]  S. Whiteheart Platelet granules: surprise packages. , 2011, Blood.

[32]  J. Freedman,et al.  Platelets and the immune continuum , 2011, Nature Reviews Immunology.

[33]  T. Ratliff,et al.  Platelet CD40L at the interface of adaptive immunity. , 2011, Thrombosis research.

[34]  J. Benito,et al.  Elevated TGF‐β1 levels might protect HCV/ HIV‐coinfected patients from liver fibrosis , 2011, European journal of clinical investigation.

[35]  L. Tian,et al.  Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China , 2010, Transfusion medicine.

[36]  M. Yeaman Bacterial-platelet interactions: virulence meets host defense. , 2010, Future microbiology.

[37]  M. Yeaman Platelets in defense against bacterial pathogens , 2009, Cellular and Molecular Life Sciences.

[38]  I. Marzi,et al.  Platelet Factor 4 Is Highly Upregulated in Dendritic Cells after Severe Trauma , 2009, Molecular medicine.

[39]  H. Dietz,et al.  Circulating Transforming Growth Factor-&bgr; in Marfan Syndrome , 2009, Circulation.

[40]  M. Elvers,et al.  Integrins in platelet activation , 2009, Journal of thrombosis and haemostasis : JTH.

[41]  T. Voyno-Yasenetskaya,et al.  Lipopolysaccharide Stimulates Platelet Secretion and Potentiates Platelet Aggregation via TLR4/MyD88 and the cGMP-Dependent Protein Kinase Pathway1 , 2009, The Journal of Immunology.

[42]  M. Dierich,et al.  Human platelets attenuate Aspergillus species via granule-dependent mechanisms. , 2008, The Journal of infectious diseases.

[43]  W. Almawi,et al.  Polymorphisms of the human platelet alloantigens HPA‐1, HPA‐2, HPA‐3, and HPA‐4 in ischemic stroke , 2008, American journal of hematology.

[44]  J. Harty,et al.  Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. , 2008, Blood.

[45]  Michael R. Yeaman,et al.  Unifying themes in host defence effector polypeptides , 2007, Nature Reviews Microbiology.

[46]  Stephen R. Clark,et al.  Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood , 2007, Nature Medicine.

[47]  E. Ricciotti,et al.  Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. , 2006, Blood.

[48]  J. Freedman,et al.  Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. , 2006, Blood.

[49]  P. Kubes,et al.  Platelets express functional Toll-like receptor-4. , 2005, Blood.

[50]  T. J. Neiva,et al.  Effect of pathogenic yeasts on human platelet aggregation , 2003 .

[51]  Z. Ruggeri,et al.  Von Willebrand factor, platelets and endothelial cell interactions , 2003, Journal of thrombosis and haemostasis : JTH.

[52]  M. Selsted,et al.  Antimicrobial Peptides from Human Platelets , 2002, Infection and Immunity.

[53]  M. Yeaman The role of platelets in antimicrobial host defense. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  V. Praloran,et al.  Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. , 1997, The American journal of medicine.

[55]  Xing-li Wang,et al.  Circulating transforming growth factor β1 and coronary artery disease , 1997 .

[56]  J. Pawlotsky,et al.  Hepatitis C virus infection and autoimmune thrombocytopenic purpura. , 1995, Journal of hepatology.

[57]  S. Banks,et al.  Epidemiology of thrombocytopenia in HIV inlection , 1992, European journal of haematology.

[58]  M. Sporn,et al.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.

[59]  R. Blasczyk,et al.  HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. , 2013, Human gene therapy.

[60]  Yang Yang,et al.  Microparticles are the basic storage units for different proteins in platelet granules. , 2012, Blood.

[61]  A. Kirk,et al.  Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. , 2005, Experimental hematology.

[62]  J. I. dos Santos,et al.  Effect of pathogenic yeasts on human platelet aggregation. , 2003, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[63]  D. Wilcken,et al.  Circulating transforming growth factor beta 1 and coronary artery disease. , 1997, Cardiovascular research.